Estimations des analystes de Wall Street pour MaxCyte, Inc. (MXCT): objectif de cours de consensus, recommandations achat/conserver/vente et prévisions de revenus, BPA et EBITDA pour les prochains exercices.
Consensus des analystes
| Achat fort | 0 |
| Achat | 4 |
| Conserver | 2 |
| Vente | 0 |
| Vente forte | 0 |
| Analystes au total | 6 |
| Note moyenne (1-5) | 0.67 |
Surprises de Résultats Récentes
| Date | BPA Réel | BPA Estimé | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.08 | ||
| 2026-08-12 | $-0.08 | $-0.09 | +11.1% |
| 2026-05-12 | $-0.04 | $-0.10 | +60.0% |
| 2026-03-24 | $-0.06 | $-0.08 | +25.0% |
| 2025-11-12 | $-0.12 | $-0.11 | -9.1% |
| 2025-08-06 | $-0.12 | $-0.10 | -20.0% |
| 2025-05-07 | $-0.10 | $-0.10 | +0.0% |
| 2025-03-11 | $-0.10 | $-0.12 | +16.7% |
Ratios de valorisation
| Prix / Valeur comptable | 0.80 |
| EV / EBITDA | -4.29 |
| Rendement du dividende | 0.00% |
Compte de Résultat (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | $12.3M | $14.0M | $16.7M | $21.6M | $26.2M | $33.9M | $44.3M | $41.3M | $38.6M | $33.0M |
| Coût des Ventes | $1.3M | $1.5M | $1.8M | $2.5M | $2.8M | $3.6M | $5.1M | $4.7M | $7.1M | $6.2M |
| Marge Brute | $11.0M | $12.5M | $14.8M | $19.1M | $23.4M | $30.2M | $39.2M | $36.5M | $31.5M | $26.8M |
| R&D | $4.7M | $11.3M | $11.2M | $17.6M | $17.7M | $15.4M | $19.5M | $23.8M | $22.2M | $20.8M |
| Frais Généraux | $9.0M | $10.5M | $12.0M | $13.4M | $15.7M | $31.7M | $44.5M | $57.0M | $56.4M | $47.0M |
| Charges Opérationnelles | $13.7M | $21.8M | $23.3M | $31.5M | $34.5M | $48.4M | $66.5M | $84.8M | $82.7M | $72.1M |
| Résultat Opérationnel | -$2.7M | -$9.3M | -$8.4M | -$12.4M | -$11.1M | -$18.2M | -$27.4M | -$48.3M | -$51.2M | -$45.3M |
| EBITDA | -$2.6M | -$9.1M | -$7.9M | -$11.6M | -$9.9M | -$16.6M | -$20.7M | -$33.8M | -$36.3M | -$39.5M |
| Charges d'Intérêt | $637800 | $625300 | $614600 | $681100 | $825600 | $1.0M | $126900 | 0 | 0 | 0 |
| Résultat Avant Impôts | -$3.3M | -$9.9M | -$8.9M | -$12.9M | -$11.8M | -$19.1M | -$23.6M | -$37.9M | -$41.1M | -$44.6M |
| Impôts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Résultat Net | -$3.3M | -$9.9M | -$8.9M | -$12.9M | -$11.8M | -$19.1M | -$23.6M | -$37.9M | -$41.1M | -$44.6M |
| BPA | $-0.10 | $-0.20 | $-0.17 | $-0.24 | $-0.18 | $-0.22 | $-0.19 | $-0.37 | $-0.39 | $-0.42 |
| BPA Dilué | $-0.10 | $-0.20 | $-0.17 | $-0.24 | $-0.18 | $-0.22 | $-0.19 | $-0.37 | $-0.39 | $-0.42 |
| Actions en Circulation (Diluées) | $33.5M | $48.6M | $51.2M | $56.4M | $69.5M | $90.6M | $101.7M | $103.3M | $104.8M | $106.4M |
Prix
| Prix | $1.18 |
| Capitalisation | $126M |
| Bourse | NASDAQ |
| Pays | US |
Entreprises liées: ARMP · AVR · CATX · LNSR · NNOX · OWLT · PRE
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de MXCT: Vue d'ensemble · Financiers · Valorisation · Statistiques · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions